Jimenez, NataliaReig Torras, OscarMarin Aguilera, MercedesAversa, CaterinaFerrer Mileo, LauraFont, AlbertRodriguez Vida, AlejoCliment, Miguel ÁngelCros, SaraChirivella, IsabelDomenech, MontserratFigols, MarionaGonzález Billalabeitia, EnriqueJiménez Peralta, DanielRodriguez Carunchio, LeonardoGarcia Esteve, SamuelGarcía de Herrero, MartaRibal, María JoséPrat Aparicio, AleixMellado González, Begoña2023-04-272023-04-272022-09-292072-6694https://hdl.handle.net/2445/197342Background: Androgen deprivation therapy (ADT) and docetaxel (DX) combination is a standard therapy for metastatic hormone-sensitive prostate cancer (mHSPC) patients. (2) Methods: We investigate if tumor transcriptomic analysis predicts mHSPC evolution in a multicenter retrospective biomarker study. A customized panel of 184 genes was tested in mRNA from tumor samples by the nCounter platform in 125 mHSPC patients treated with ADT+DX. Gene expression was correlated with castration-resistant prostate cancer-free survival (CRPC-FS) and overall survival (OS). (3) Results: High expression of androgen receptor (AR) signature was independently associated with longer CRPC-FS (hazard ratio (HR) 0.6, 95% confidence interval (CI) 0.3-0.9; p = 0.015), high expression of estrogen receptor (ESR) signature with longer CRPC-FS (HR 0.6, 95% CI 0.4-0.9; p = 0.019) and OS (HR 0.5, 95% CI 0.2-0.9, p = 0.024), and lower expression of tumor suppressor genes (TSG) (RB1, PTEN and TP53) with shorter OS (HR 2, 95% CI 1-3.8; p = 0.044). ARV7 expression was independently associated with shorter CRPC-FS (HR 1.5, 95% CI 1.1-2.1, p = 0.008) and OS (HR 1.8, 95% CI 1.2-2.6, p = 0.004), high ESR2 was associated with longer OS (HR 0.5, 95% CI 0.2-1, p = 0.048) and low expression of RB1 was independently associated with shorter OS (HR 1.9, 95% CI 1.1-3.2, p = 0.014). (4) Conclusions: AR, ESR, and TSG expression signatures, as well as ARV7, RB1, and ESR2 expression, have a prognostic value in mHSPC patients treated with ADT+DX.17 p.application/pdfengcc by (c) Jimenez, Natalia et al., 2023http://creativecommons.org/licenses/by/3.0/es/Càncer de pròstataAndrògensProstate cancerAndrogensinfo:eu-repo/semantics/article2023-04-26info:eu-repo/semantics/openAccess933113336230681